Hyperaldosteronism among black and white subjects with resistant hypertension
- PMID: 12468575
- DOI: 10.1161/01.hyp.0000040261.30455.b6
Hyperaldosteronism among black and white subjects with resistant hypertension
Abstract
Recent reports suggesting that the prevalence of primary hyperaldosteronism may be higher than historically thought have relied on an elevated plasma aldosterone concentration/plasma renin activity ratio to either diagnose or identify subjects at high risk of having primary hyperaldosteronism and have not included suppression testing of all evaluated subjects. In this prospective study of 88 consecutive patients referred to a university clinic for resistant hypertension, we determined the 24-hour urinary aldosterone excretion during high dietary salt ingestion, baseline plasma renin activity, and plasma aldosterone in all subjects. Primary hyperaldosteronism was confirmed if plasma renin activity was <1.0 ng/mL per hour and urinary aldosterone was >12 microg/24-hour during high urinary sodium excretion (>200 mEq/24-hour). Eighteen subjects (20%) were confirmed to have primary hyperaldosteronism. The prevalence of hyperaldosteronism was similar in black and white subjects. Of the 14 subjects with confirmed hyperaldosteronism who have been treated with spironolactone, all have manifested a significant reduction in blood pressure. In this population, an elevated plasma aldosterone/plasma renin activity ratio (>20) had a sensitivity of 89% and a specificity of 71% with a corresponding positive predictive value of 44% and a negative predictive value of 96%. These data provide strong evidence that hyperaldosteronism is a common cause of resistant hypertension in black and white subjects. The accuracy of these results is strengthened by having done suppression testing of all evaluated subjects.
Similar articles
-
Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.Am J Hypertens. 2005 Jun;18(6):805-12. doi: 10.1016/j.amjhyper.2005.01.002. Am J Hypertens. 2005. PMID: 15925740
-
Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing.Clin Med (Lond). 2005 Jan-Feb;5(1):55-60. doi: 10.7861/clinmedicine.5-1-55. Clin Med (Lond). 2005. PMID: 15745200 Free PMC article.
-
Normokalemic hyperaldosteronism in patients with resistant hypertension.Isr Med Assoc J. 2002 Jan;4(1):17-20. Isr Med Assoc J. 2002. PMID: 11802302
-
The role of aldosterone antagonists in the management of resistant hypertension.Curr Hypertens Rep. 2005 Oct;7(5):343-7. doi: 10.1007/s11906-005-0067-3. Curr Hypertens Rep. 2005. PMID: 16157075 Review.
-
Primary aldosteronism: diagnostic and therapeutic considerations.Curr Cardiol Rep. 2005 Nov;7(6):412-7. doi: 10.1007/s11886-005-0058-7. Curr Cardiol Rep. 2005. PMID: 16256009 Review.
Cited by
-
Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups.Endocrine. 2012 Aug;42(1):182-9. doi: 10.1007/s12020-012-9609-z. Endocrine. 2012. PMID: 22302679
-
Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.Curr Cardiol Rep. 2019 Jul 27;21(9):93. doi: 10.1007/s11886-019-1185-x. Curr Cardiol Rep. 2019. PMID: 31352525 Review.
-
An Update on Refractory Hypertension.Curr Hypertens Rep. 2022 Jul;24(7):225-234. doi: 10.1007/s11906-022-01185-6. Epub 2022 Apr 6. Curr Hypertens Rep. 2022. PMID: 35384577 Free PMC article. Review.
-
Resistant hypertension and aldosteronism.Curr Hypertens Rep. 2007 Nov;9(5):353-9. doi: 10.1007/s11906-007-0066-7. Curr Hypertens Rep. 2007. PMID: 18177580 Review.
-
Hypertension.Ann Intern Med. 2019 May 7;170(9):ITC65-ITC80. doi: 10.7326/AITC201905070. Ann Intern Med. 2019. PMID: 31060074
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical